IMVT - Immunovant, Inc.
IEX Last Trade
24.61
0.455 1.849%
Share volume: 44,615
Last Updated: Fri 27 Dec 2024 08:30:28 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$24.16
0.46
1.88%
Fundamental analysis
25%
Profitability
25%
Dept financing
3%
Liquidity
50%
Performance
25%
Performance
5 Days
-0.12%
1 Month
-10.44%
3 Months
-8.17%
6 Months
-1.04%
1 Year
-40.93%
2 Year
49.94%
Key data
Stock price
$24.61
DAY RANGE
$23.93 - $25.58
52 WEEK RANGE
$25.39 - $45.58
52 WEEK CHANGE
-$38.93
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Peter Salzmann
Region: US
Website: immunovant.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: immunovant.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.
Recent news